Skip to content

Study · Animal study (in vivo) · rat · 2014

4 results

Bone healing with oxytocin-loaded microporous β-TCP bone substitute in ectopic bone formation model and critical-sized osseous defect of rat.

Park JW, Kim JM, Lee HJ, Jeong SH, Suh JY, Hanawa T

Journal of clinical periodontology11 Dec 2013Cited by 15 (Europe PMC)

PMID24256613 (opens in a new tab)DOI10.1111/jcpe.12198 (opens in a new tab)PepBankPUB-24256613
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with subcutaneous beta-TCP implants, oxytocin-loaded beta-TCP clearly enhanced ectopic bone formation compared with unloaded control.

    In plain wordsIn rats, a bone substitute loaded with oxytocin produced more bone under the skin than the same material without oxytocin.

    Peptide
    Oxytocin
    Outcome
    IncreaseEctopic bone formation
    Study

    ratn: not reported in source

    Subcutaneous ectopic bone formation model
    Comparator
    Unloaded beta-TCP control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · local delivery on a microporous beta-TCP carrierAs given in this study (rat).

    Source sentences

    Summary
    The OT-loaded β-TCP clearly enhanced ectopic bone formation compared with the unloaded control group.
    1 context sentence
    Summary · context
    Both the ectopic and new bone formation induced by the OT-loaded microporous β-TCP powder was histomorphometrically compared with unloaded β-TCP in a subcutaneous ectopic bone formation model and calvarial critical-sized defects (CSDs) in 45 rats.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with subcutaneous beta-TCP implants, the high initial oxytocin dose (250 μg) significantly increased ectopic bone formation at an early time-point compared with the lower dose (50 μg).

    In plain wordsIn rats, a higher oxytocin dose on the bone substitute gave more early bone formation than a lower dose.

    Peptide
    Oxytocin
    Outcome
    IncreaseEctopic bone formation at an early healing time-point, high versus low dose
    Study

    ratn: not reported in source

    Subcutaneous ectopic bone formation model
    Comparator
    Oxytocin 50 μg
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    250 μg · local delivery on a microporous beta-TCP carrierAs given in this study (rat).

    Measurements

    Oxytocin dose, high
    250 μg
    ectopic bone formation
    Oxytocin dose, low
    50 μg
    ectopic bone formation

    Source sentences

    Summary
    A High initial OT dose (250 μg) significantly increased ectopic bone formation at an early healing time-point compared with a lower OT dose (50 μg).
    1 context sentence
    Summary · context
    Both the ectopic and new bone formation induced by the OT-loaded microporous β-TCP powder was histomorphometrically compared with unloaded β-TCP in a subcutaneous ectopic bone formation model and calvarial critical-sized defects (CSDs) in 45 rats.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with calvarial critical-sized defects, oxytocin-loaded samples showed greater new bone formation than unloaded samples.

    In plain wordsIn rats with skull bone defects, samples loaded with oxytocin grew more new bone than samples without it.

    Peptide
    Oxytocin
    Outcome
    IncreaseNew bone formation in calvarial critical-sized defects
    Study

    ratn: not reported in source

    Calvarial critical-sized defect model
    Comparator
    Unloaded beta-TCP control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · local delivery on a microporous beta-TCP carrierAs given in this study (rat).

    Source sentences

    Summary
    The OT-loaded samples displayed greater new bone formation in the rat calvarial CSDs.
    1 context sentence
    Summary · context
    Both the ectopic and new bone formation induced by the OT-loaded microporous β-TCP powder was histomorphometrically compared with unloaded β-TCP in a subcutaneous ectopic bone formation model and calvarial critical-sized defects (CSDs) in 45 rats.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with calvarial critical-sized defects, extensive new bone formation was achieved with the higher oxytocin dose.

    In plain wordsIn rats with skull bone defects, the higher oxytocin dose on the bone substitute gave extensive new bone growth.

    Peptide
    Oxytocin
    Outcome
    IncreaseNew bone formation in calvarial defects with the higher oxytocin dose
    Study

    ratn: not reported in source

    Calvarial critical-sized defect model
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · local delivery on a microporous beta-TCP carrierAs given in this study (rat).

    Source sentences

    Summary
    Extensive new bone formation was achieved in the calvarial CSDs with the higher OT dose.
    1 context sentence
    Summary · context
    Both the ectopic and new bone formation induced by the OT-loaded microporous β-TCP powder was histomorphometrically compared with unloaded β-TCP in a subcutaneous ectopic bone formation model and calvarial critical-sized defects (CSDs) in 45 rats.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.